Regentis Biomaterials Ltd. (RGNT) Stock

NYSE: RGNTHealthcare company in the medical instruments & supplies industry, based in Herzliya, USA.

Regentis Biomaterials stock price chart

RGNT interactive chart →

RGNT stock quote & key statistics

Regentis Biomaterials earnings per share

Income →
Earnings per share

Regentis Biomaterials revenue & net income

Income →
RevenueNet income

Regentis Biomaterials annual financials

Income statement →
Fiscal yearRevenueNet incomeEPS
FY2025$0-$13.6M—
FY2024$0$4.8M—
FY2023$0-$4.1M—
FY2022$0-$1.4M—

Fiscal year ending December 31. Source: company filings via EODHD.

About Regentis Biomaterials Ltd.

Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.

Regentis Biomaterials stock FAQ

What is the Regentis Biomaterials stock ticker symbol?

Regentis Biomaterials Ltd. trades on the NYSE under the ticker symbol RGNT.

What sector and industry is Regentis Biomaterials in?

Regentis Biomaterials Ltd. is classified in the Healthcare sector, Medical Instruments & Supplies industry.

What were Regentis Biomaterials's revenue and earnings last fiscal year?

Regentis Biomaterials reported revenue of $0 and net income of -$13.6M in fiscal 2025.

When did Regentis Biomaterials go public?

Regentis Biomaterials stock began trading on December 4, 2025.

Medical Instruments & Supplies stocks

All Healthcare stocks →